Weekly Recap | Pulse Biosciences -0.24%, $73 target flagged by brokers

The Week

Pulse Biosciences (PLSE.US) edged down 0.24% this week to close at $53.11, while the S&P 500 fell 0.80%, meaning PLSE outperformed by about 0.56 percentage points. Trading spanned only four sessions and amplitude reached 21.16%. On Tuesday (Sep 8) the stock dropped to $47.70 intraday and closed at $48.79. On Wednesday it rebounded sharply to an intraday high of $58.90 before settling at $52.97. Over the next two sessions it held above $50, closing Friday at $53.11. The pattern was a choppy, fading week.\n\n## Key Events\n\nThere was no company-specific product approval, earnings release, or major regulatory news in the week. Public headlines mostly placed PLSE alongside broader medical-device movers. On 10 Sep, after an institution reportedly flagged a $73 high target, Pulse Biosciences rose 9.19% and led the healthcare sector intraday. Intraday news also mentioned biotech names like Modular Medical, InnovAge, and Pyxis, but PLSE itself offered limited new business updates. The week appeared driven by sector sentiment and elevated single-stock volatility rather than fresh company fundamentals.\n\n## Analyst Ratings\n\nFive brokers cover the stock: four rate it buy and one overweight, with no hold, underweight, or sell. The consensus rating is strong buy, with a consensus target of $50.8, about 4.35% below the current price. The target range remains wide, from $35 to $73, a spread of more than double. PLSE ranks 49th out of 142 medical-device companies in its industry.\n\n## The Week Ahead\n\nThe macro calendar is heavier next week. On Tuesday (Sep 15) the New York Empire State manufacturing index is due, and on Wednesday (Sep 16) retail sales, retail sales ex-autos, NAHB housing market index, import prices, and EIA crude inventories will be released. For PLSE itself, the key question is whether the $73 high target mentioned this week attracts sustained buying interest and whether support near $50 holds.\n\n## In Short\n\nPulse Biosciences had a small weekly loss but very wide swings, and it still beat the broader market. Brokers are collectively at strong buy, yet the consensus target sits below spot while the high target is far above it, underscoring wide disagreement on this medical-device name. The valuation is also rich at over 38x price-to-book, and the latest session showed small and medium orders as net sellers. The tension to watch is whether this pricing gap resolves through volume, or gets pushed around further by the coming macro data.\n\nThis article is generated by LongbridgeAI from market data, for information only and not investment advice.